Tag
#Quality Of Earnings
30 articles
The Blind Claim: The Three Hidden Failure Points Where Your Enterprise Value Is Actually Decided
Buy-side diligence rebuilds your EBITDA from your PMS data. The three failure points where enterprise value is decided — and how sellers defend each one.
The Fifth Seat: I Asked an AI to Build a Seller's Advisor Team. It Named Four.
I asked an AI to build a dental practice seller's advisor team. It named four seats and omitted sell-side diligence — the one seat paid to defend your number.
The Graded Exam: Why Your Earnout Is Scored by the Person Who Owes the Money
An earnout is 10-30% of a dental practice sale, paid only if targets are hit — targets the buyer models, under operations the buyer controls, measured on the buyer's books. The mechanics, the tax trap, and the five clauses that un-tilt the table.
The Legislative Squeeze and the Pricing of Risk: Why CT HB 5127 Matters to Your M&A Exit
Connecticut HB 5127 bans healthcare providers from promoting medical credit cards like CareCredit starting January 1, 2027. Why the law is a template, how buyers will price financing-dependent case acceptance, and the defense.
The Treatment Trajectory: Why Patients Don't Leave Your Practice — They Fall Out of It
A Treatment Trajectory is the documented arc of a patient's care — diagnosis, acceptance, completion, re-care. Why patient loyalty is an architecture, not a sentiment, and how buyers price trajectory data at exit.
Toxic Top-Line: The Revenue That Counts Until Someone Checks
A $12M practice with clean books carried $227K of production a buyer's analyst refused to price. Real revenue, collected and booked — but not defensible. One code ratio exposed $650K of enterprise value, and the fix was paperwork.
The CPA Trap: Why Financial Historians Cannot Fight Data Wars
Your CPA is a trusted advisor and a skilled financial historian — and structurally unequipped to defend a practice sale. Why QoE teams bypass the General Ledger, attack the Clinical Ledger, and what a seller's defense actually requires.
The Broker's Prospectus: A Marketing Brochure, Not a Forensic Baseline
A broker's prospectus is a marketing brochure, not due diligence. Why buying a dental practice on reported collections and a few KPIs is a faith-based multiple — and what a forensic clinical baseline reveals that the prospectus hides.
The Consultant's Mirage: Why Standard Advice Fails a Dental QoE Audit
The standard dental consultant advice — boost production, cut overhead — is exactly what gets your EBITDA slaughtered in a buyer's Quality of Earnings audit.
Personal Goodwill: Why a Dental Buyer Can Withhold Your Cash
Goodwill is most of a dental practice's price — but buyers only pay full for goodwill that transfers. How personal goodwill and the key-person discount cost you at close.
Operational Due Diligence: Know Your Dental Practice Baseline
The broker, lender, and CPA all give sound advice — but none establishes your operational baseline. Why buyers and sellers need forensic operational due diligence before they act.
Dental Practice Broker: The Incentive Problem Nobody Explains
You almost certainly need a dental practice broker. But the success-fee model means defending your number through diligence was never their job. Here's the gap — and why it costs so much.
The LOI Is Not the Deal: The Chronological Anatomy of a 90-Day Enterprise Value Extraction
85% of dental practice sellers lose enterprise value after the buyer's Quality of Earnings audit. Here is the exact chronological anatomy of what happens inside the 90-day exclusivity window — and how $4.2M becomes $3.15M.
The Overhead Lie: Why Your Practice's 60% Is Hiding a Valuation Problem
Your 60% overhead looks fine on a P&L. An institutional buyer sees something different entirely. Here's what the benchmarks actually mean at exit — and what they hide.
The Defense Gap: How Private Equity Monetizes Asymmetric Diligence in Dental M&A
Buy-side diligence teams spend $1.2-3M per transaction while sellers spend almost nothing. SRS Acquiom data shows 85% of deals face post-LOI adjustments. Here's why the clinical data layer is where dental-specific value extraction happens.
What Is My Dental Practice Worth? Why the Answer Depends Entirely on Who's Buying
The value of your dental practice depends entirely on who is buying. Here is how individual buyers and institutional buyers calculate it — and why those are two different numbers.
Dental Practice Exit Strategy: The 5-Year Forensic Blueprint for an Institutionally Auditable Sale
A year-by-year dental practice exit strategy for building a practice that institutional buyers pay premium multiples for — the forensic blueprint starting 5 years before you sell.
The $250,000 Audit: How Retroactive Payer Downgrades Destroy Enterprise Value
A $25,000 insurance chargeback becomes a $250,000 enterprise value reduction at a 10x multiple. Here's how retroactive payer audits and QoE extrapolation compound to destroy dental practice valuations.
Legal For A Price: How Algorithmic Denials Are Stealing Your Clinical Autonomy
Insurance carriers are deploying AI-driven denial algorithms that override clinical judgment at scale. A 90% overturn rate on appeal proves the denials are engineered for deterrence — but only 1% are ever contested.
The KPIs That Kill Your Multiple: Which Dental Practice Metrics Institutional Buyers Actually Score
Not all dental KPIs matter at exit. Here are the metrics PE-backed buyers weight most, the thresholds that move multiples, and the vanity metrics they ignore entirely.
How DSOs Actually Evaluate Your Dental Practice: The 11 Underwriting Criteria They Score But Never Publish
Former NADG regional director reveals the 11 criteria DSO underwriting teams actually score — and the specific thresholds that separate premium multiples from discount ones.
The Same Playbook: What a Harvard Hospital Study Tells Us About the Future of Dental Practice Valuations
A Harvard study on PE-owned hospitals revealed a 13% rise in ER deaths after acquisition. The same debt-loading, cost-cutting playbook runs in dental M&A — and understanding it is the difference between a defended exit and a seven-figure re-trade.
Governance Debt: The Compounding Liability Silently Eroding Your Practice's Enterprise Value
Governance debt — compliance gaps, undocumented SOPs, key-person risk — compounds silently and surfaces during due diligence. Here's how to quantify and eliminate it before a buyer's algorithm does.
Before the First Pitch: What Opening Day Teaches About Building a Practice That Lasts
A-Rod's career framework — focus, visualization, work ethic, and resilience — maps directly to the practices that exit at premium multiples. The outcome is decided before the first pitch.
The Merry Go Round Tax: What High Turnover Is Really Costing Your Practice
High turnover is not a staffing problem. It is a tax — paid in lost production, eroded patient trust, training drag, and a QoE audit fingerprint that costs you at the multiple.
The Algorithmic Denial Machine: How Payer AI Is Weaponizing Your Radiographs
Insurance payers are deploying pixel-level AI to deny claims at scale. The same weaponization PE firms use during QoE is coming to every claim you submit.
The Data Room Nobody Builds: What Buyers See That Sellers Never Prepare
A QoE team spends 30 days dismantling the story you spent 30 years building. Sellers who pre-audit their data room dictate the terms of their exit.
The Silent Margin Collapse: Clinical Judgment as Enterprise Value Destruction
A single D4910-to-D1110 downgrade costs $70. Repeated daily across 3 locations, it erases $504,000 in enterprise value at a 6x multiple.
The Due Diligence Ambush: How PE Weaponizes Your Data to Hijack Your Exit
Private Equity QoE teams extract raw PMS data to systematically dismantle your EBITDA. A $3M group lost $13.8M in enterprise value to unsanitized data.
The Data-Driven Practice Advantage: Predictable Revenue, Minimized Risk, and EBITDA That Survives the Buyer's QoE
The data-driven practice advantage is not dashboards or software — it is predictable revenue, quantified risk, and an EBITDA figure that survives the buyer's Quality of Earnings audit without adjustment.